WO2001022954A3 - Indolyl-3-glyoxylic acid derivatives serving as antitumor agents - Google Patents

Indolyl-3-glyoxylic acid derivatives serving as antitumor agents Download PDF

Info

Publication number
WO2001022954A3
WO2001022954A3 PCT/EP2000/009390 EP0009390W WO0122954A3 WO 2001022954 A3 WO2001022954 A3 WO 2001022954A3 EP 0009390 W EP0009390 W EP 0009390W WO 0122954 A3 WO0122954 A3 WO 0122954A3
Authority
WO
WIPO (PCT)
Prior art keywords
indolyl
acid derivatives
glyoxylic acid
antitumor agents
derivatives serving
Prior art date
Application number
PCT/EP2000/009390
Other languages
German (de)
French (fr)
Other versions
WO2001022954A2 (en
Inventor
Bernd Nickel
Thomas Klenner
Gerald Bacher
Thomas Beckers
Peter Emig
Juergen Engel
Erik Bruyneel
Guenter Kamp
Kirsten Peters
Original Assignee
Baxter Healthcare Sa
Bernd Nickel
Thomas Klenner
Gerald Bacher
Thomas Beckers
Peter Emig
Juergen Engel
Erik Bruyneel
Guenter Kamp
Kirsten Peters
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19946301A external-priority patent/DE19946301A1/en
Priority to MXPA02002824A priority Critical patent/MXPA02002824A/en
Priority to NZ517988A priority patent/NZ517988A/en
Priority to AT00967789T priority patent/ATE459356T1/en
Priority to DE50015879T priority patent/DE50015879D1/en
Priority to HU0202788A priority patent/HUP0202788A3/en
Priority to YUP-227/02A priority patent/RS51302B/en
Priority to EP00967789A priority patent/EP1218006B1/en
Priority to AU77829/00A priority patent/AU783436B2/en
Priority to KR1020027003937A priority patent/KR100759242B1/en
Priority to PL364811A priority patent/PL199576B1/en
Priority to JP2001526166A priority patent/JP2003510274A/en
Application filed by Baxter Healthcare Sa, Bernd Nickel, Thomas Klenner, Gerald Bacher, Thomas Beckers, Peter Emig, Juergen Engel, Erik Bruyneel, Guenter Kamp, Kirsten Peters filed Critical Baxter Healthcare Sa
Priority to SK407-2002A priority patent/SK287533B6/en
Priority to EEP200200169A priority patent/EE200200169A/en
Priority to IL14867000A priority patent/IL148670A0/en
Priority to UA2002043433A priority patent/UA75872C2/en
Priority to CA2386069A priority patent/CA2386069C/en
Priority to BR0014378-2A priority patent/BR0014378A/en
Publication of WO2001022954A2 publication Critical patent/WO2001022954A2/en
Priority to IL148670A priority patent/IL148670A/en
Priority to NO20021367A priority patent/NO322614B1/en
Priority to IS6319A priority patent/IS6319A/en
Publication of WO2001022954A3 publication Critical patent/WO2001022954A3/en
Priority to BG106639A priority patent/BG106639A/en
Priority to HR20020369A priority patent/HRP20020369A2/en
Priority to HK03101178.9A priority patent/HK1048941B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

The invention relates to the use of N-substituted indol-3- glyoxylamides of general formula (I) for treating tumors, in particular, in cases of drug resistance and metastatic carcinoma, and as angiogenesis inhibitors having distinctly fewer side effects, in particular, distinctly lower neurotoxicity. The invention also relates to medicaments containing the inventive compounds.
PCT/EP2000/009390 1999-09-28 2000-09-26 Indolyl-3-glyoxylic acid derivatives serving as antitumor agents WO2001022954A2 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
SK407-2002A SK287533B6 (en) 1999-09-28 2000-09-26 Medicament for the treatment of multidrug-resistant tumors or angiogenesis and metastasis inhibition
EEP200200169A EE200200169A (en) 1999-09-28 2000-09-26 Indolyl-3-glyoxylic acid derivatives with therapeutically valuable properties
NZ517988A NZ517988A (en) 1999-09-28 2000-09-26 Antitumour compositions comprising indolyl-3-glyoxylic acid derivatives
IL14867000A IL148670A0 (en) 1999-09-28 2000-09-26 Indolyl-3-glyoxylic acid derivatives comprising therapeutically valuable properties
HU0202788A HUP0202788A3 (en) 1999-09-28 2000-09-26 Indolyl-3-glyoxylic acid derivatives serving as antitumor agents and pharmaceutical compositions containing them
YUP-227/02A RS51302B (en) 1999-09-28 2000-09-26 Indolyl-3-glyoxylic acid derivatives comprising therapeutically valuable properties
EP00967789A EP1218006B1 (en) 1999-09-28 2000-09-26 Indolyl-3-glyoxylic acid derivatives comprising therapeutically valuable properties
AU77829/00A AU783436B2 (en) 1999-09-28 2000-09-26 Indolyl-3-glyoxylic acid derivatives comprising therapeutically valuable properties
KR1020027003937A KR100759242B1 (en) 1999-09-28 2000-09-26 Indolyl-3-glyoxylic acid derivatives comprising therapeutically valuable properties
PL364811A PL199576B1 (en) 1999-09-28 2000-09-26 Indolyl-3-glyoxylic acid derivatives serving as antitumor agents
JP2001526166A JP2003510274A (en) 1999-09-28 2000-09-26 Indolyl-3-glyoxylic acid derivatives having therapeutically important properties
MXPA02002824A MXPA02002824A (en) 1999-09-28 2000-09-26 Indolyl-3-glyoxylic acid derivatives serving as antitumor agents.
BR0014378-2A BR0014378A (en) 1999-09-28 2000-09-26 Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties
AT00967789T ATE459356T1 (en) 1999-09-28 2000-09-26 INDOLYL-3-GLYOXYLIC ACID DERIVATIVES WITH THERAPEUTIC VALUABLE PROPERTIES
DE50015879T DE50015879D1 (en) 1999-09-28 2000-09-26 INDOLYL-3-GLYOXYLIC ACID DERIVATIVES WITH THERAPEUTICALLY VALUABLE PROPERTIES
UA2002043433A UA75872C2 (en) 1999-09-28 2000-09-26 Indolyl-3- glyoxylic acid with useful therapeutic properties
CA2386069A CA2386069C (en) 1999-09-28 2000-09-26 Indolyl-3-glyoxylic acid derivatives as antitumor agents
IL148670A IL148670A (en) 1999-09-28 2002-03-13 Indolyl-3-glyoxylic acid derivatives comprising therapeutically valuable properties
NO20021367A NO322614B1 (en) 1999-09-28 2002-03-19 Indolyl-3-glycosyl acid derivatives having therapeutically valuable properties
IS6319A IS6319A (en) 1999-09-28 2002-03-21 Indolyl-3-glyoxy acid derivatives containing useful therapeutic properties
BG106639A BG106639A (en) 1999-09-28 2002-04-23 Indolyl-3-glyoxylic acid derivatives comprising therapeutically valuable properties
HR20020369A HRP20020369A2 (en) 1999-09-28 2002-04-26 Indolyl-3-glyoxylic acid derivatives comprising therapeutically valuable properties
HK03101178.9A HK1048941B (en) 1999-09-28 2003-02-18 Indolyl-3-glyoxylic acid derivatives comprising therapeutically valuable properties

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19946301A DE19946301A1 (en) 1998-04-02 1999-09-28 Antitumor agents and angiogenesis inhibitors having low neurotoxicity, comprise indole-3-glyoxylamide derivatives, are effective against resistant and metastasis-forming carcinomas
DE19946301.8 1999-09-28

Publications (2)

Publication Number Publication Date
WO2001022954A2 WO2001022954A2 (en) 2001-04-05
WO2001022954A3 true WO2001022954A3 (en) 2002-03-28

Family

ID=7923485

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/009390 WO2001022954A2 (en) 1999-09-28 2000-09-26 Indolyl-3-glyoxylic acid derivatives serving as antitumor agents

Country Status (32)

Country Link
EP (1) EP1218006B1 (en)
JP (1) JP2003510274A (en)
KR (1) KR100759242B1 (en)
CN (1) CN1301712C (en)
AR (1) AR025885A1 (en)
AT (1) ATE459356T1 (en)
AU (1) AU783436B2 (en)
BG (1) BG106639A (en)
BR (1) BR0014378A (en)
CA (1) CA2386069C (en)
CZ (1) CZ303246B6 (en)
DE (1) DE50015879D1 (en)
DZ (1) DZ3196A1 (en)
EE (1) EE200200169A (en)
ES (1) ES2342042T3 (en)
GE (1) GEP20043250B (en)
HK (1) HK1048941B (en)
HR (1) HRP20020369A2 (en)
HU (1) HUP0202788A3 (en)
IL (2) IL148670A0 (en)
IS (1) IS6319A (en)
MX (1) MXPA02002824A (en)
NO (1) NO322614B1 (en)
NZ (1) NZ517988A (en)
PL (1) PL199576B1 (en)
RS (1) RS51302B (en)
RU (1) RU2282444C2 (en)
SK (1) SK287533B6 (en)
TW (1) TWI269654B (en)
UA (1) UA75872C2 (en)
WO (1) WO2001022954A2 (en)
ZA (1) ZA200202556B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962300A1 (en) * 1999-12-23 2001-06-28 Asta Medica Ag New N-benzylindolyl glyoxylic acid derivatives are useful as antitumor agents
JP2003535078A (en) 2000-05-31 2003-11-25 アストラゼネカ アクチボラグ Indole derivatives with vascular damage activity
DE10037310A1 (en) 2000-07-28 2002-02-07 Asta Medica Ag New indole derivatives and their use as medicines
EP1484329A1 (en) * 2003-06-06 2004-12-08 Zentaris GmbH Indole derivatives with apoptosis inducing activity
EP1595878A1 (en) * 2004-05-15 2005-11-16 Zentaris GmbH Indole derivatives with apoptosis inducing activity
EP1641777A1 (en) * 2003-06-05 2006-04-05 Zentaris GmbH Indole derivatives with apoptosis-inducing effect
US20050124623A1 (en) 2003-11-26 2005-06-09 Bender John A. Diazaindole-dicarbonyl-piperazinyl antiviral agents
CA2567813C (en) * 2004-05-23 2015-11-24 Gerard M. Housey Theramutein modulators
EP1809279B1 (en) * 2004-11-08 2013-05-29 Baxter International Inc. Particulate compositions of tubulin inhibitor
US20060100432A1 (en) 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
WO2006073973A2 (en) 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Novel benzylamine derivatives as cetp inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US7851476B2 (en) 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
EP2091532A1 (en) * 2006-11-28 2009-08-26 Ziopharm Oncology, Inc. Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
CA2850022C (en) 2011-09-27 2018-05-01 Dr. Reddy's Laboratories, Ltd. 5 - benzylaminomethyl - 6 - aminopyrazolo [3,4-b] pyridine derivatives as cholesteryl ester-transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
WO2014144715A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
CN109111501B (en) * 2017-06-23 2022-04-22 首都医科大学 Fatty amino acid modified indole ethanol derivative, and synthesis, activity and application thereof
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636150A1 (en) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituted indole-3-glyoxylamides with antiasthmatic, antiallergic and immunosuppressive / immunomodulating effects
WO1999046237A1 (en) * 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases
WO1999051224A1 (en) * 1998-04-02 1999-10-14 Asta Medica Aktiengesellschaft Indolyl-3-glyoxylic acid derivatives with antitumoral activity
WO1999055696A1 (en) * 1998-04-28 1999-11-04 Arzneimittelwerk Dresden Gmbh New hydroxyindoles, their use as phosphodiesterase 4 inhibitors and method for producing same
JP2000239252A (en) * 1999-02-16 2000-09-05 Mitsubishi Chemicals Corp Indole derivative
WO2000067802A1 (en) * 1999-05-10 2000-11-16 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
AU671865B2 (en) * 1992-10-20 1996-09-12 Toray Industries, Inc. Eosinophil infiltration inhibitor
CA2286038A1 (en) 1997-04-08 1998-10-15 Banyu Pharmaceutical Co., Ltd. Cancerous metastasis-associated gene
CA2322162A1 (en) * 1998-02-25 1999-09-02 Genetics Institute, Llc Inhibitors of phospholipase enzymes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636150A1 (en) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituted indole-3-glyoxylamides with antiasthmatic, antiallergic and immunosuppressive / immunomodulating effects
WO1999046237A1 (en) * 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases
WO1999051224A1 (en) * 1998-04-02 1999-10-14 Asta Medica Aktiengesellschaft Indolyl-3-glyoxylic acid derivatives with antitumoral activity
WO1999055696A1 (en) * 1998-04-28 1999-11-04 Arzneimittelwerk Dresden Gmbh New hydroxyindoles, their use as phosphodiesterase 4 inhibitors and method for producing same
JP2000239252A (en) * 1999-02-16 2000-09-05 Mitsubishi Chemicals Corp Indole derivative
WO2000067802A1 (en) * 1999-05-10 2000-11-16 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 12 3 January 2001 (2001-01-03) *

Also Published As

Publication number Publication date
EP1218006A2 (en) 2002-07-03
KR20030019295A (en) 2003-03-06
ATE459356T1 (en) 2010-03-15
CA2386069C (en) 2012-08-14
JP2003510274A (en) 2003-03-18
GEP20043250B (en) 2004-06-25
ZA200202556B (en) 2003-08-27
IS6319A (en) 2002-03-21
KR100759242B1 (en) 2007-09-18
CN1376064A (en) 2002-10-23
HUP0202788A3 (en) 2003-02-28
CZ20021005A3 (en) 2004-01-14
NZ517988A (en) 2004-10-29
HK1048941A1 (en) 2003-04-25
YU22702A (en) 2004-12-31
DE50015879D1 (en) 2010-04-15
SK287533B6 (en) 2011-01-04
CN1301712C (en) 2007-02-28
AR025885A1 (en) 2002-12-18
NO20021367L (en) 2002-05-22
NO20021367D0 (en) 2002-03-19
AU783436B2 (en) 2005-10-27
DZ3196A1 (en) 2001-04-05
EE200200169A (en) 2003-04-15
PL199576B1 (en) 2008-10-31
HUP0202788A2 (en) 2003-01-28
BG106639A (en) 2002-12-29
CA2386069A1 (en) 2001-04-05
ES2342042T3 (en) 2010-07-01
EP1218006B1 (en) 2010-03-03
UA75872C2 (en) 2006-06-15
BR0014378A (en) 2003-07-29
IL148670A (en) 2009-09-01
CZ303246B6 (en) 2012-06-20
NO322614B1 (en) 2006-11-06
AU7782900A (en) 2001-04-30
PL364811A1 (en) 2004-12-13
HRP20020369A2 (en) 2004-12-31
TWI269654B (en) 2007-01-01
RS51302B (en) 2010-12-31
SK4072002A3 (en) 2003-11-04
MXPA02002824A (en) 2003-07-21
RU2282444C2 (en) 2006-08-27
WO2001022954A2 (en) 2001-04-05
HK1048941B (en) 2007-09-21
IL148670A0 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
WO2001022954A3 (en) Indolyl-3-glyoxylic acid derivatives serving as antitumor agents
HUP0104964A3 (en) Quinazoline derivatives as angiogenesis inhibitors, process for their preparation and medicaments containing the compounds
YU11501A (en) 4,4-biarylpiperidine derivatives with opioid receptor activity
WO2002008190A3 (en) Novel heteroaryl derivatives and use thereof as anti-tumour agents
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
EP1277754A4 (en) Imidazopyridine derivatives
HUP0301117A3 (en) Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
GB0114286D0 (en) Nucleoside Derivatives
HUP0203453A3 (en) Quinazoline derivatives as vegf inhibitors, process for their preparation, pharmaceutical compositions containing them and their use
HUP0301046A3 (en) Quinazoline derivatives for the treatment of tumours, process for their preparation and pharmaceutical compositions containing them
WO1997015555A3 (en) Imidazole derivatives and the use thereof as nitrogen monoxide synthase inhibitors
HUP0203509A3 (en) Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same
EP1140840A4 (en) -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
BG106003A (en) New n-cyanomethylamides and compositions as protease inhibitors
HUP0200210A3 (en) Camptothecin derivatives having antitumor activity, process for their preparation and pharmaceutical compositions containing them
ZA200203165B (en) 5-aryl-1H-1,2,4-triazole compounds as inhibitors of cyclo-oxygenase-2 and pharmaceutical compositions containing them.
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
WO2000045800A3 (en) Immunosurpressive effects of pteridine derivatives
WO2004078748A3 (en) Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
BG105731A (en) 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
HUP0203422A3 (en) Imidazole derivatives as phosphodiesterase vii inhibitors, process for their preparation and pharmaceutical compositions containing them
WO2002010152A3 (en) Novel indole derivatives and their use as medicaments
IL154755A0 (en) Antitumor theraphy comprising distamycin derivatives
WO2001090136A3 (en) Triterpenoid derivatives
TW200504051A (en) Novel acridine derivatives and their use as medicaments

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-227/02

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AU BG BR BY CA CN CZ DZ EE GE HR HU ID IL IN IS JP KG KR KZ LT LV MK MX NO NZ PL RO RU SG SI SK TR UA US UZ YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 148670

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/002824

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: PV2002-1005

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 4072002

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2001 526166

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 517988

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1020027003937

Country of ref document: KR

Ref document number: IN/PCT/2002/399/KOL

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2386069

Country of ref document: CA

Ref document number: 008134499

Country of ref document: CN

Ref document number: 2002/00815

Country of ref document: TR

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BG BR BY CA CN CZ DZ EE GE HR HU ID IL IN IS JP KG KR KZ LT LV MK MX NO NZ PL RO RU SG SI SK TR UA US UZ YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2000967789

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002/02556

Country of ref document: ZA

Ref document number: 200202556

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2000 106639

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 77829/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: P20020369A

Country of ref document: HR

ENP Entry into the national phase

Ref document number: 2002 2002111866

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2000967789

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027003937

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2002-1005

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 517988

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 517988

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 77829/00

Country of ref document: AU